Denosumab for Smoldering Multiple Myeloma

Status Active, not recruiting

Clinical Trial Summary

This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.

Clinical Trial Description

This is an open label, Phase II trial of denosumab 120mg subcutaneous (SC) for patients with smoldering multiple myeloma (SMM). Subjects will be recruited from the James P. Wilmot Cancer Center, University of Rochester in Rochester, New York. Patients seen in the inpatient or outpatient setting with histologically confirmed SMM will be evaluated for this study. 20 patients will be treated as follows: Denosumab: day 1 = 120mg SC every 4 weeks for 12 cycles. Cycles will be 28 days in length. Patients will be followed after completion of the study per standard of care for progression free survival for an additional 2 years after the last dose of denosumab. All patients will take daily vitamin D and calcium supplements of at least 1200mg elemental calcium and 800IU of vitamin D unless documented hypercalcemia develops on study. Pre-existing hypocalcemia must be corrected prior to initiating therapy with denosumab. Serum vitamin D levels will be checked during screening and should be repleted to a total 25-hydroxyvitamin D level ≥30ng/mL. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03839459
Study type	Interventional
Source	University of Rochester
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	April 19, 2019
Completion date	June 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01222286` - Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma	Phase 2
Withdrawn	`NCT00503763` - Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma	Phase 2
Active, not recruiting	`NCT02916771` - Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma	Phase 2
Completed	`NCT01955395` - Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma	N/A
Completed	`NCT01237054` - Imaging in MGUS, SMM and MM	Phase 2
Completed	`NCT02903381` - A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma	Phase 2
Active, not recruiting	`NCT03301220` - A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma	Phase 3
Active, not recruiting	`NCT03236428` - Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma	Phase 2
Completed	`NCT01718899` - Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma	Phase 1
Completed	`NCT00112827` - Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma	Phase 1/Phase 2
Completed	`NCT00099047` - Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma	Phase 2
Terminated	`NCT01248455` - A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma	Phase 2
Active, not recruiting	`NCT03289299` - Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant	Phase 2
Not yet recruiting	`NCT06365060` - Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Active, not recruiting	`NCT02415413` - Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma	Phase 2
Completed	`NCT01302886` - Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma	Phase 2
Recruiting	`NCT05841550` - The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma	Phase 1/Phase 2
Recruiting	`NCT06183489` - Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma	Phase 2
Recruiting	`NCT06383143` - Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Active, not recruiting	`NCT02886065` - A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM	Phase 1